The global Interventional Cardiology Devices Market size was valued at USD 11.3 billion in 2025 and is projected to grow from USD 12.1 billion in 2026 to USD 19.8 billion by 2033, registering a CAGR of 7.3% from 2026 to 2033. North America dominated the global market with the largest revenue share of 46.1% in 2025, driven by the rising prevalence of cardiovascular diseases (CVDs), increasing adoption of minimally invasive procedures, technological advancements in coronary intervention devices, and expanding access to advanced cardiac care. Growing rates of obesity, hypertension, diabetes, sedentary lifestyles, smoking, and aging populations continue to increase the global burden of coronary artery disease (CAD), creating sustained demand for interventional cardiology procedures and devices.

Interventional cardiology has become a cornerstone of modern cardiovascular treatment by enabling physicians to diagnose and treat complex heart conditions through minimally invasive catheter-based procedures. Compared to open-heart surgery, these procedures offer shorter hospital stays, faster recovery, reduced complications, and improved clinical outcomes. Continuous innovation in coronary stents, guidewires, balloons, imaging technologies, and intravascular diagnostic systems is further improving procedural precision and long-term patient outcomes.

Healthcare providers are increasingly adopting advanced interventional devices to improve procedural efficiency, reduce repeat interventions, and support personalized treatment strategies for patients with complex coronary artery disease.

Growing PCI Volumes Supporting Market Expansion

The increasing number of Percutaneous Coronary Intervention (PCI) procedures remains one of the strongest drivers of market growth.

Recent developments supporting procedural growth include:

• Rising prevalence of coronary artery disease
• Increasing incidence of acute coronary syndromes
• Expanding use of minimally invasive treatment approaches
• Improved catheter-based intervention technologies
• Growing availability of outpatient cardiac intervention centers
• Enhanced intravascular imaging and physiological assessment

PCI continues to be the preferred treatment option for restoring blood flow through narrowed or blocked coronary arteries while reducing the risk of heart attacks and other cardiovascular complications. The procedure offers an effective alternative to conventional surgery for many patients requiring coronary revascularization.

Download a free sample copy of the Interventional Cardiology Devices Market report to understand detailed coverage and inclusions in the final report

According to findings presented during the SCAI Scientific Sessions in May 2025, 408,060 outpatient PCI procedures performed between 2020 and 2022 were evaluated. Approximately 98.2% were conducted in hospital outpatient departments, while 1.8% were performed in ambulatory surgery centers. The study demonstrated increasing PCI utilization in ambulatory settings while maintaining low 30-day adverse event rates, including mortality, stroke, and bleeding, all remaining below 2%.

Emerging Industry Trend: AI and Precision Imaging Transforming Cardiac Interventions

Artificial intelligence and advanced intravascular imaging technologies are rapidly transforming interventional cardiology. AI-assisted procedural planning, real-time lesion assessment, automated image analysis, and predictive clinical decision support are improving procedural accuracy while reducing complications.

Technologies such as Intravascular Ultrasound (IVUS), Optical Coherence Tomography (OCT), Fractional Flow Reserve (FFR), and physiological lesion assessment are increasingly being integrated into routine clinical practice. These innovations enable cardiologists to optimize stent placement, evaluate plaque characteristics, and personalize treatment strategies for complex coronary lesions.

Key Market Trends & Insights

Coronary Stents Continue to Lead Product Demand

• By product, the coronary stents segment accounted for the largest revenue share of 48.3% in 2025.
• Growing prevalence of cardiovascular diseases and increasing adoption of minimally invasive coronary interventions continue to support segment growth.
• Continuous advancements in drug-eluting stents (DES), thinner strut technologies, and enhanced delivery systems are improving procedural outcomes and reducing restenosis rates.
• In August 2024, Medtronic introduced the Onyx Frontier Drug-Eluting Stent (DES) following CE Mark approval, featuring an advanced delivery system designed to improve procedural performance.

Coronary Artery Disease Represents the Largest Procedure Segment

• By procedures, the coronary artery disease (CAD) segment held the largest revenue share of 52.2% in 2025.
• Increasing incidence of CAD and growing demand for effective coronary revascularization continue to drive procedural volumes.
• Advances in PCI techniques, IVUS, OCT imaging, bioresorbable scaffolds, drug-eluting balloons, and second-generation drug-eluting stents are improving treatment outcomes for both stable and acute CAD patients.
• Clinical research continues to focus on reducing restenosis, minimizing stent thrombosis, and optimizing treatment for complex coronary lesions.

Hospitals Remain the Primary End-use Setting

• By end use, the hospital segment accounted for the largest market revenue share in 2025.
• Hospitals manage highly complex cardiovascular cases, including acute myocardial infarction, multivessel coronary artery disease, chronic total occlusions, and emergency PCI procedures.
• Integrated cardiac care pathways, advanced catheterization laboratories, multidisciplinary cardiac teams, and intensive post-procedural monitoring continue to strengthen hospital demand for interventional cardiology devices.

Looking for more specific insights? Customize this report to suite your business needs

Regional Highlights

• Largest Regional Market: North America (46.1% revenue share, 2025)
• Leading Country: United States

North America continues to dominate the global market due to advanced healthcare infrastructure, widespread adoption of innovative cardiovascular technologies, high procedural volumes, and favorable reimbursement policies. Increasing investments in structural heart interventions, digital cardiology, and minimally invasive treatment techniques are expected to further support regional growth.

Market Size & Forecast

• Market Size (2025): USD 11.3 Billion
• Estimated Market Size (2026): USD 12.1 Billion
• Projected Market Size (2033): USD 19.8 Billion
• CAGR (2026–2033): 7.3%

The growing burden of cardiovascular disease continues to increase demand for advanced interventional treatment solutions. According to the CDC, cardiovascular disease caused 919,032 deaths in the United States during 2023, including 371,506 deaths attributed to coronary heart disease. Approximately 805,000 heart attacks occur annually across the country, including 605,000 first-time heart attacks, highlighting the continuing need for early diagnosis and minimally invasive coronary interventions.

Competitive Landscape

Leading manufacturers operating in the interventional cardiology devices market continue to strengthen their market presence through product innovation, strategic acquisitions, research collaborations, and expansion of advanced cardiovascular technology portfolios. Companies are investing heavily in next-generation coronary stents, intravascular imaging systems, catheter technologies, robotic-assisted interventions, and AI-enabled procedural guidance to improve clinical outcomes.

Industry participants are increasingly focusing on:

• Drug-eluting stent innovation
• Intravascular imaging technologies
• AI-assisted procedural planning
• Robotic-assisted cardiovascular interventions
• Structural heart intervention devices
• Global expansion and strategic partnerships

Continuous investment in research and development is accelerating the commercialization of advanced devices designed to improve procedural precision, reduce complications, and enhance long-term cardiovascular outcomes.

Explore Grand View Horizon to see global and regional level statistics related to the Interventional Cardiology Devices Market

Key Interventional Cardiology Devices Companies

The following companies are among the leading participants operating in the global interventional cardiology devices market:

• Abbott
• Medtronic
• Boston Scientific Corporation
• Cardinal Health
• Koninklijke Philips N.V.
• Terumo Corporation
• Alvimedica
• Teleflex Incorporated
• B. Braun SE
• Biosensors International Group, Ltd.
• Meril Life Sciences Pvt. Ltd.
• BIOTRONIK
• ACIST Medical Systems
• ASAHI INTECC CO., LTD.
• Cook
• Medinol
• Merit Medical Systems
• Numed, Inc.
• OpSens (Acquired by Haemonetics)
• Zeon Medical (KANEKA CORPORATION)

Conclusion

The global interventional cardiology devices market is poised for sustained growth as cardiovascular disease continues to remain one of the leading causes of mortality worldwide. Rising PCI procedure volumes, continuous advancements in coronary stents, AI-powered imaging, intravascular diagnostics, and minimally invasive treatment technologies are transforming cardiac care. Increasing healthcare investments, expanding access to advanced cardiovascular treatment, and ongoing innovation in precision cardiology are expected to drive long-term market expansion while improving patient outcomes across both developed and emerging healthcare systems.

Looking for a report customized to your requirements? Explore our Custom Research Offering

Grand View Research offers

• Focused market intelligence reports on specific geographies or high-growth segments
• Extended forecast timelines for long-term planning
• Competitor Benchmarking and Supply Chain Analysis
• Inclusion of regulatory and policy assessments
• Inclusion of custom data models, KPIs, or applications unique to your business
• Specific high-impact Data Decks and Tables to support effective decision making

And much more…